{"name": "olutasidenib", "category": "drug", "content": "Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is taken by mouth. The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis. Olutasidenib was approved for medical use in the United States in December 2022, based on the phase 1 results of a phase 1/2 trial.   == Medical uses == Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.   == Society and culture ==   === Names === Olutasidenib is the international nonproprietary name.   == References ==   == Further reading ==   == External links == \"Olutasidenib\". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT02719574 for \"Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation\" at ClinicalTrials.gov"}